| AASLD

Sociodemographic Risk Factors for Depression in Patients With Chronic Liver Disease

Read more about Sociodemographic Risk Factors for Depression in Patients With Chronic Liver Disease

Lucia Rivera‐Matos, Sarah Andrews, Sheila Eswaran – 26 May 2022

Closing the disparity gap and optimizing advanced hepatocellular carcinoma care in the hispanic community

Read more about Closing the disparity gap and optimizing advanced hepatocellular carcinoma care in the hispanic community

Julio A. Gutierrez, Leticia Z. Bresnahan, Elena Rios, Priya Wanchoo, Adelfo San Valentin, Margot Embree Fisher – 26 May 2022

Renal dysfunction after liver transplantation for polycystic liver disease

Read more about Renal dysfunction after liver transplantation for polycystic liver disease

Jeremy S. Nayagam, Aamir Nawaz, Katie Ramos, Matthew E. Cramp, Catriona Shaw, Sapna Shah, Deepak Joshi, Nigel Heaton, Abid Suddle – 26 May 2022

Gut‐specific inhibition of PPARα as a novel approach of NAFLD treatment

Read more about Gut‐specific inhibition of PPARα as a novel approach of NAFLD treatment

Lanjing Zhang, Grace L. Guo – 26 May 2022

The unfolded protein response to PI*Z alpha‐1 antitrypsin in human hepatocellular and murine models

Read more about The unfolded protein response to PI*Z alpha‐1 antitrypsin in human hepatocellular and murine models

Yuanqing Lu, Liqun R. Wang, Jungnam Lee, Naweed S. Mohammad, Alek M. Aranyos, Calvin Gould, Nazli Khodayari, Regina A. Oshins, Craig G. Moneypenny, Mark L. Brantly – 26 May 2022 – Alpha‐1 antitrypsin (AAT) deficiency (AATD) is an inherited disease caused by mutations in the serpin family A member 1 (SERPINA1, also known as AAT) gene. The most common variant, PI*Z (Glu342Lys), causes accumulation of aberrantly folded AAT in the endoplasmic reticulum (ER) of hepatocytes that is associated with a toxic gain of function, hepatocellular injury, liver fibrosis, and hepatocellular carcinoma.